Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$172.11
-0.1%
$182.46
$163.33
$251.99
$49.33B0.251.97 million shs2.38 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$83.00
+1.2%
$78.95
$57.52
$117.91
$32.54B1.464.33 million shs3.45 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.91
+2.1%
$17.51
$14.17
$34.13
$2.00B0.741.18 million shs1.16 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.03%-0.21%-1.86%-25.86%-26.37%
DexCom, Inc. stock logo
DXCM
DexCom
+1.23%-3.13%-2.90%+17.40%-28.42%
NovoCure Limited stock logo
NVCR
NovoCure
+2.05%+5.98%+0.11%-7.49%-16.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
1.4673 of 5 stars
0.00.00.04.30.61.71.9
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9558 of 5 stars
4.24.03.34.03.02.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.7984 of 5 stars
3.55.00.04.72.22.51.9
NovoCure Limited stock logo
NVCR
NovoCure
4.1504 of 5 stars
3.34.00.04.52.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00
N/AN/AN/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2227.38% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5018.67% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8383.32% Upside

Current Analyst Ratings Breakdown

Latest DXCM, ABMD, NVCR, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/6/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $196.00
5/5/2025
DexCom, Inc. stock logo
DXCM
DexCom
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$280.00 ➝ $224.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$260.00 ➝ $185.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$192.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.87B2.36$15.99 per share10.76$89.57 per share1.92
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B7.85$2.09 per share39.75$5.38 per share15.43
NovoCure Limited stock logo
NVCR
NovoCure
$621.71M3.21N/AN/A$3.39 per share5.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2428.5911.001.638.47%15.74%7.29%8/7/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3458.0433.742.3014.29%30.14%10.11%7/24/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)

Latest DXCM, ABMD, NVCR, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.42%N/A79.39%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest DXCM, ABMD, NVCR, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.49
1.44

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000286.61 million286.10 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,320111.49 million101.40 millionOptionable

Recent News About These Companies

Wedbush Estimates NovoCure's FY2026 Earnings (NASDAQ:NVCR)
Novocure Announces Upcoming Investor Events

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abiomed stock logo

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$172.11 -0.10 (-0.06%)
Closing price 06/16/2025 03:59 PM Eastern
Extended Trading
$171.42 -0.69 (-0.40%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$83.00 +1.01 (+1.23%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$82.88 -0.12 (-0.15%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.91 +0.36 (+2.05%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$18.03 +0.12 (+0.67%)
As of 06/16/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.